Preferred Label : Hydrogel-based Resiquimod STM-416;
NCIt synonyms : Resiquimod-containing Hydrogel STM-416;
NCIt definition : An injectable biodegradable hydrogel-based, intra-tumoral extended-release (ER) formulation
containing the imidazoquinolinamine resiquimod, a Toll-like receptor (TLR) 7 and 8
agonist, with potential immunostimulating and antineoplastic activities. Upon intra-tumoral
administration at the site and time of surgery involving transurethral resection of
bladder tumor, the hydrogel-based resiquimod STM-416 locally releases resiquimod for
an extended period and binds to TLR7 and 8, which are found mainly on dendritic cells
(DCs), macrophages, and B-lymphocytes, and activates the TLR signaling pathway. This
results in the induction of the nuclear translocation of transcription activator nuclear
factor kappa-B (NF-kB) and activation of other transcription factors. This leads to
the induction of NF-kB-dependent genes and increases cytokine production, especially
interferon-alpha (INF-a), which results in the enhancement of T-helper 1 (Th1) immune
responses. Activation of DCs also results in the activation of cytotoxic T-lymphocyte
(CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and
8, members of the TLR family, play fundamental roles in the activation of the immune
system.;
Molecule name : STM 416; STM-416;
Origin ID : C201569;
concept_is_in_subset
- has_target
